Investor Presentaiton

Portfolio offering provides strategic advantage +139% INVESTOR 20 DAY 23 2020 GUARDANT™ 2021 2022 H1 2023 Market adoption of concurrent blood and tissue testing 69% Of oncologists choose their testing partner based on "one-stop-shop" ordering¹ *Stated use of liquid and tissue CGP prior to 1L NSCLC treatment. 2019-2022 are averages. 2023 includes Q1 and Q2 data. 1. Guardant360 Brand Tracker, Q2 2023. 80

View entire presentation